TABLE 1.

Adverse events (AE) by treatment cohort. A) Number of participants reporting categorized ^a AE; B) Number of participants with ARIA; C) Number of AEs distributed by severity

	Placebo	Allo 2 mg	Allo 4 mg	Allo 6–18 mg
	(N = 6)	(N = 6)	(N = 6)	(N = 6)	P‐value c
A) Serious AE, N (%) b
Gastrointestinal disorders	0	1 (17)	0	0	1.0
AE, N (%) b
Cardiac disorders	0	0	0	1 (17)	1.0
Gastrointestinal disorders	0	1 (17)	1 (17)	0	1.0
General disorders and administration site conditions	2 (33)	1 (17)	1 (17)	2 (33)	1.0
Infections and infestations	2 (33)	1 (17)	1 (17)	1 (17)	1.0
Injury, poisoning, and procedural complications	1 (17)	0	0	0	1.0
Metabolism and nutrition disorders	0	0	1 (17)	0	1.0
Musculoskeletal and connective tissue disorders	2 (33)	0	0	0	0.22
Nervous system disorders	0	1 (17)	1 (17)	0	1.0
Respiratory, thoracic, and mediastinal disorders	0	1 (17)	0	2 (33)	0.57
Skin and subcutaneous tissue disorders	0	1 (17)	2 (33)	1 (17)	0.88
Surgical and medical procedures	0	0	1 (17)	0	1.0
B) ARIA, N (%) b	0 (0)	0 (0)	0 (0)	0 (0)	1.0

C) AE severity, N (%) d	Placebo	Allo 2 mg	Allo 4 mg	Allo 6‐18 mg	P‐value e
Mild	5 (62.5)	6 (75)	8 (53)	6 (60)	0.73
Moderate	3 (37.5)	2 (25)	6 (40)	3 (30)
Severe	0	0	1 (7)	1 (10)

^aMedDRA classifications. Abbreviation: ARIA, amyloid related imaging abnormalities.

^bN (%) = no. of participants; Participants may have reported more than one event within a classification.

^cFisher's exact test comparing proportion of participants reporting an event across treatment cohort.

^dN (%) = no. of events.

^eFisher's exact test comparing distribution of the most severe AE reported by a participant across treatment cohorts.